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Polychlorinated biphenyls (PCBs) have been
well studied for possible effects on newborns
and infants after it was determined that PCBs
could effectively pass through the placental
barrier and that they were associated with
lower birth weights (1). Jacobson et al. (2)
found that children exposed in utero to PCBs
had delayed central nervous system function-
ing. Subsequent studies then conﬁrmed that
for this same cohort, reductions in cognitive
function were associated with higher in utero
PCB exposure at 4 years of age (3), followed
by lower IQs at 11 years of age (4). These
studies seem to indicate a potential link
between PCBs and neurodevelopment. 
Although many theories exist about how
PCBs affect neurodevelopment, the main
hypothesis involves disruption of thyroid
hormone homeostasis (5). Thyroid hor-
mones regulate neuronal proliferation and
cell migration and differentiation, including
control over when differentiation begins and
when cell proliferation ends (6). Studies in
the rat showed that transport of thyroid hor-
mones to the brain requires thyroxine (T4)
to pass through the blood–brain barrier
bound to the thyroid hormone transport
protein transthyretin (TTR) (7). Although
PCBs show some binding affinity for TTR
(8), hydroxylated metabolites of PCBs (HO-
PCBs) have much higher in vitro binding
afﬁnities that can be as high as 12 times the
binding afﬁnity of the natural ligand T4 (9).
Binding to TTR is not limited to HO-
PCBs. Other halogenated phenolic com-
pounds such as pentachlorophenol (PCP),
halogenated phenols, and tetrabromobisphe-
nol A (10,11) also have strong afﬁnities for
TTR. Recently, PCP was found to be the
dominant phenolic compound in whole
blood from Inuit (12) and Latvian and
Swedish ﬁsh eaters (13). Thus, we must con-
sider the combined effect of halogenated
phenolic compounds in plasma that exhibit
similar toxicological properties to HO-PCBs
(10,14,15). A recent review described the
formation and retention of HO-PCBs and
the main metabolites that have been previ-
ously identiﬁed in plasma (16).
HO-PCBs decrease circulating levels of
thyroid hormones in rats through competi-
tive binding to TTR (17). TTR is also
responsible for retinol transport by form-
ing a dimer with retinol-binding protein.
Thus, circulating retinol concentrations
can also be affected by PCB and HO-PCB
exposure (18).
The fetus may be especially vulnerable
to PCB and HO-PCB exposure. When fetal
mice were exposed in utero to 4´-HO-
CB79, a metabolite of polychlorinated
biphenyl congener number 77 (CB77),
both maternal and fetal plasma T4 levels
decreased signiﬁcantly compared to controls
(19). In this same study, fetal plasma had
twice the 4´-HO-CB79 concentration of
the maternal plasma (20). These experi-
ments were recently repeated on pregnant
rats orally exposed to 4-HO-CB107 (21),
one of the main HO-PCBs found in human
plasma (12,13). In that study, both mater-
nal and fetal plasma concentrations of thy-
roid hormones were reduced by exposure to
4-HO-CB107. Fetal total T4 concentrations
decreased by 89% of that of the controls
(21). The decreased plasma T4 levels also
decreased forebrain and cerebellum T4 con-
centrations compared to controls (21),
which may lead to a neurodevelopmental
effect. PCP also decreases brain T4 availabil-
ity in rats (22). Another interesting ﬁnding
of the 4-HO-CB107 rat dosing study was
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Concentrations of polychlorinated biphenyls (PCBs), hydroxylated metabolites of PCBs
(HO-PCBs) and octachlorostyrene (4-HO-HpCS), and pentachlorophenol (PCP) were deter-
mined in umbilical cord plasma samples from three different regions of Québec. The regions
studied included two coastal areas where exposure to PCBs is high because of marine-food–based
diets—Nunavik (Inuit people) and the Lower North Shore of the Gulf of St. Lawrence (subsis-
tence fishermen)—and a southern Québec urban center where PCB exposure is at background
levels (Québec City). The main chlorinated phenolic compound in all regions was PCP.
Concentrations of PCP were not signiﬁcantly different among regions (geometric mean concen-
tration 1,670 pg/g, range 628–7,680 pg/g wet weight in plasma). The ratio of PCP to polychlori-
nated biphenyl congener number 153 (CB153) concentration ranged from 0.72 to 42.3. Sum
HO-PCB (ΣHO-PCBs) concentrations were different among regions, with geometric mean con-
centrations of 553 (range 238–1,750), 286 (103–788), and 234 (147–464) pg/g wet weight
plasma for the Lower North Shore, Nunavik, and the southern Québec groups, respectively.
Lower North Shore samples also had the highest geometric mean concentration of sum PCBs
(sum of 49 congeners; ΣPCBs), 2,710 (525–7,720) pg/g wet weight plasma. ΣPCB concentra-
tions for Nunavik samples and southern samples were 1,510 (309–6,230) and 843 (290–1,650)
pg/g wet weight plasma. Concentrations (log transformed) of ΣHO-PCBs and ΣPCBs were sig-
nificantly correlated (r = 0.62, p < 0.001), as were concentrations of all major individual
HO-PCB congeners and individual PCB congeners. In Nunavik and Lower North Shore samples,
free thyroxine (T4) concentrations (log transformed) were negatively correlated with the sum of
quantitated chlorinated phenolic compounds (sum PCP and ΣHO-PCBs; r = –0.47, p = 0.01, n =
20) and were not correlated with any PCB congeners or ΣPCBs. This suggests that PCP and
HO-PCBs are possibly altering thyroid hormone status in newborns, which could lead to neu-
rodevelopmental effects in infants. Further studies are needed to examine the effects of chlori-
nated phenolic compounds on thyroid hormone status in newborns. Key words: hydroxylated
metabolites, pentachlorophenol, polychlorinated biphenyls, retinol, thyroxine, umbilical cord
plasma. Environ Health Perspect 110:411–417 (2002). [Online 12 March 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p411-417sandau/abstract.html
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Articlesan accumulation of 4-HO-CB107 in fetal
plasma, liver, and brain (21).
Thus, prenatal exposure to PCBs, HO-
PCBs, and PCP may all lead to thyroid
hormone disruption and possibly neurode-
velopmental effects. Analysis of umbilical
cord plasma is of special interest because it
provides a direct indication of in utero expo-
sure to developmental toxicants. PCBs have
been measured previously in umbilical cord
plasma (23,24), but the present study, to our
knowledge, is one of the first studies to
examine chlorinated phenolic compounds in
this biological medium. Participants were
from populations with different PCB expo-
sures caused by differences in dietary habits.
Retinol and thyroid hormone status [tri-
iodothyronine (T3), free T4, thyroid-stimulat-
ing hormone (TSH), and thyroxine-binding
globulin (TBG)] were determined in samples
from remote maritime populations, so the
relationship between chlorinated phenolic
compounds and these biological markers
could be explored. 
Materials and Methods
Samples. Plasma samples were obtained dur-
ing various umbilical cord blood surveys
conducted from 1993 to 1996 in Québec
(25,26). These surveys took place in
Nunavik (northern Québec), the Lower
North Shore of the Gulf of St. Lawrence,
and southern Québec (Québec City; Figure
1). The population in the Québec City area
receives background PCB exposure similar
to that of the general population of Canada,
whereas the former two coastal areas com-
prise small settlements of people with unusu-
ally high PCB exposure. The traditional diet
of Nunavik Inuit include seal and beluga
blubber, which contain concentrations of
PCBs in the order of several milligrams per
kilogram (27,28). The diet of the Lower
North Shore subsistence ﬁsh-eating popula-
tion includes ﬁsh, sea mammals, and seabird
eggs (28). Ten samples from each region
were randomly selected for chlorinated phe-
nolic compound and PCB residue analysis
from all samples collected during the sur-
veys. Nunavik samples were all from Inuit
newborns, southern Québec samples from
Caucasian newborns, and Lower North
Shore samples from three Caucasians and
seven aboriginal neonates.
Standards and chemicals. PCBs are
numbered according to the numbering
scheme as described by Ballschmiter and Zell
(29). Hydroxylated PCBs and their methoxy-
lated derivatives are given the appropriate
Ballschmiter PCB number according to their
chlorination pattern. The HO- or MeO-
functional groups are numbered thereafter, as
described by Letcher et al. (16). Note that
the numbering of two congeners in our
previous publication (12) has changed:
4-HO-CB109 is now 4-HO-CB107, and
4-HO-CB107 is now 4´-HO-CB108.
The following 13C12-labeled standards
were acquired from Wellington Laboratories
(Guelph, ON, Canada) and were used as an
internal recovery standard mixture: 4´-HO-
CB120, 4´-HO-CB159, 4´-HO-CB172,
and 4-HO-CB187. [13C6]PCP was pur-
chased from Cambridge Isotope Laboratories
(Andover, MA, USA) and was used for PCP
quantitation. Labeled PCBs ([13C12]CB-
118, 153, 180, and 194) were used as inter-
nal recovery standards, and [13C12]CB-138
was used as the performance standard
for PCB analysis. [13C12]PCB standards
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Figure 1. Sample locations for the three populations: Nunavik (northern Québec), Lower North Shore (Gulf
of St. Lawrence), and southern Québec (Québec City).
Hudson’s Bay
Ontario
Quebec
Nunavik
Atlantic Ocean
Lower North Shore
Southern population
Table 1. Concentrations (picograms per gram wet weight plasma) of halogenated phenolic compounds
and ΣPCBs in umbilical cord plasma from three regions in Québec (n = 10 for each region). 
Nunavik Lower North Shore Southern Québec
Compound GM Min Max GM Min Max GM Min Max
PCP 1,870 889 7,680 1,430 628 3,640 1,740 1,020 4,090
4-HO-HpCS 31 3 177 34 9 139 5 2 21
HO-PCBs
4-HO-CB187 47 13 155 95 54 250 28 10 97
4-HO-CB146 37 4 134 81 16 507 12 4 58
3-HO-CB153 19 4 65 23 10 74 6 3 14
4-HO-CB107/ 12 3 44 49 6 168 11 3 43
4´-HO-CB108
3´-HO-CB138 10 3 35 22 9 92 5 3 16
4´-HO-CB172 10 3 43 20 8 75 4 1 11
4,4´-diHO-CB202a 63 1 5 5 1 13 4 3 17
3-HO-CB187 4 ND 34 7 2 21 1 ND 3
4-HO-CB193 3 1 17 3 1 8 1 0 5
4´-HO-CB120 2 1 4 7 3 20 2 ND 6
4´-HO-CB208a 21 5311 1 1 N D 3
3´-HO-CB180 2 ND 14 5 1 23 1 ND 3
4´-HO-CB130 1 ND 3 2 ND 27 1 ND 3
4´-HO-CB199a < 1 ND 4 < 1 ND 7 < 1 ND < 1
Sum HO-PCBs 286 103 788 553 238 1,750 234 147 464
HO-PCBs:PCBs 0.19 0.08 0.41 0.20 0.08 0.56 0.19 0.04 0.46
Abbreviations: GM, geometric mean; Max, maximum; Min, minimum; ND, not detected. 
aTentative identifications based on information in the review by Letcher et al. (16). Note that 4-HO-CB107 and
4´-HO-CB108 coelute and were quantitated as a single peak. The 4-hydroxy-heptachlorostyrene (4-HO-HpCS) was quan-
titated using relative response factors from the heptachlorinated MeO-PCB standards.were purchased from Cambridge Isotope
Laboratories (Andover, MA, USA). The
HO-PCB performance standard, 4´-Me-4-
MeO-CB112, was a custom synthesis by B.
Wightman (Carleton University, Ottawa,
ON, Canada).
All solvents were residue-analysis grade
and purchased from EM Science (Gibbstown,
NJ, USA). Merck Silica gel (Grade 60, 70-230
mesh, 60Å) was purchased from Aldrich
Chemical Company, Inc. (Milwaukee, WI,
USA). Sulfuric acid (trace-metal grade) was
purchased from Fisher Scientiﬁc (Pittsburgh,
PA, USA).
Methodology and instrumentation. A
thorough description of the methodology and
instrumentation used for these analyses was
described previously (12). Methodology was
altered slightly for this study. Umbilical cord
plasma samples ranged from 1.63 to 10.4 g
and samples were spiked with 20 µL
[13C12]HO-PCB internal standard mixture
(100 pg/µL), 20 µL [13C6]PCP (100 pg/µL),
and with 10 µL [13C12]PCB internal standard
mixture (2.5 ng/µL) before extraction. The
ﬁnal volume for the phenolic compound frac-
tion was 25 µL and was spiked with 4´-Me-4-
MeO-2,3,3´,5,6-pentachlorobiphenyl (5 µL)
as performance standard before analysis. The
PCB fraction was reduced to a ﬁnal volume of
100 µL and spiked with [13C12]CB138 per-
formance standard (10 µL) before analysis.
Because of low levels of PCBs in the umbilical
cord plasma samples, we analyzed PCBs by
GC-MS electron capture negative chemical
ionization mode using the same mass spec-
trometry conditions as described previously
for HO-PCBs (12). Only pentachlorinated
PCB congeners and higher are reported
because tetrachlorinated congeners and lower
do not respond well to this type of detection.
Congener-speciﬁc analysis using a character-
ized Aroclor 1:1:1 quantitation mixture
allowed the quantitation of 49 PCB con-
geners in most of the samples.
Retinol analysis was performed at the
Québec Toxicology Centre (Sainte-Foy,
Québec, Canada). Ethanol was added to the
plasma sample to denature proteins, and
retinol was extracted from the resulting solu-
tion with hexane. The hexane extract was con-
centrated under vacuum (Speed-Vac) and
redissolved in ethanol. Retinol was determined
by reverse-phase high-pressure liquid chro-
matography (Waters Corp., Milford, MA,
USA) using a C-18 column and a UV detec-
tor (325 nm). Free T4, T3, TSH, and TBG
were measured by heterogeneous competition
magnetic separation assay (Immuno 1 System;
Bayer Diagnostics, Leverkusen, Germany),
and TBG was determined by radioimmunoas-
say (DiaSorin, Stillwater, MN, USA). Thyroid
hormones and TBG determinations were con-
ducted at the Unité de Recherche en
Génétique Humaine (CHUL-CHUQ, Sainte-
Foy, Québec, Canada). Thyroid hormone
measurements were performed on Nunavik
and Lower North Shore samples but not on
southern Québec samples.
All statistical analyses were completed
with STATISTICA for Windows, version
5.1, from StatSoft, Inc. (Tulsa, OK, USA).
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Table 2. Concentrations (picograms per gram wet weight plasma) of 49 PCB congeners in umbilical cord
plasma from three regions in Québec (n = 10 for each region). 
Nunavik Lower North Shore Southern Québec
Congener GM Min Max GM Min Max GM Min Max
CB92 9 ND 60 7 ND 167 9 ND 13
CB84 27 5 141 36 6 251 16 ND 31
CB101/90 49 11 262 87 13 786 44 17 181
CB99 100 16 1,120 174 17 1,630 38 ND 116
CB97 10 ND 167 12 ND 232 8 ND 19
CB87 28 5 236 63 8 436 13 ND 27
CB85 6 2 115 14 2 150 6 ND 86
CB110 42 8 403 79 10 709 44 18 502
CB118 67 19 402 155 30 673 35 9 81
CB105 19 6 300 37 7 155 11 2 31
CB136 13 1 316 15 2 651 12 1 536
CB151 7 3 34 11 4 68 8 ND 14
CB144/135 17 ND 97 27 ND 713 13 ND 22
CB149 20 9 71 33 ND 96 30 14 103
CB134 8 1 35 11 2 86 3 ND 18
CB146 23 5 98 54 15 178 11 6 54
CB153 262 49 1,340 430 107 1,350 104 30 199
CB141 3 2 20 5 3 13 5 1 8
CB130 6 2 20 9 3 30 2 ND 4
CB137 4 1 13 6 2 15 2 ND 3
CB138/163 157 36 712 232 62 704 54 11 110
CB158 5 2 18 8 2 17 3 1 6
CB178 1 ND 9 1 ND 3 1 ND 1
CB128 7 3 27 16 6 47 4 ND 7
CB156 27 5 94 40 17 104 11 2 19
CB157 8 2 28 17 7 45 5 ND 8
CB179 2 1 5 2 ND 4 2 ND 5
CB176 1 ND 2 1 ND 1 1 ND 2
CB178 2 < 1 27 1 < 1 20 1 ND 4
CB187/182 39 7 146 102 24 297 38 13 226
CB183 14 4 135 23 6 57 7 2 12
CB185 < 1 < 1 2 1 ND 1 1 ND 2
CB174 3 2 12 4 2 9 6 1 11
CB177 5 2 13 10 4 18 4 1 7
CB171 3 1 7 6 2 13 2 1 4
CB172 2 < 1 10 6 2 14 1 ND 3
CB180 118 33 663 146 43 501 40 8 84
CB193 3 < 1 53 5 1 23 1 < 1 4
CB191 < 1 < 1 5 1 < 1 7 1 < 1 2
CB170/190 21 4 74 39 13 87 13 3 22
CB202 4 1 21 5 3 10 2 ND 3
CB200 1 < 1 22 2 1 4 1 ND 2
CB199 1 ND 4 1 ND 4 2 ND 6
CB201 4 1 17 10 2 31 7 4 11
CB196/203 8 2 26 33 7 113 15 6 95
CB195 3 1 28 5 1 32 2 ND 2
CB194 9 2 23 17 7 55 11 2 21
CB206 3 1 10 6 3 12 1 ND 2
CB209 1 < 1 1 1 < 1 2 < 1 ND 1
Sum PCBs 1,510 309 6,230 2,710 525 7,720 843 290 1,650
Abbreviations: GM, geometric mean; Max, maximum; Min, minimum; ND, not detected. 
Table 3. Concentrations of retinol, thyroid hormones, and TBG in umbilical cord plasma samples from
three regions in Québec (n = 10 for each region). 
Nunavik Lower North Shore Southern Québec
GM Min Max GM Min Max GM Min Max
Retinol (µg/L)  160 61 250 160 89 290 190 110 330
FT4 (pmol/L) 16 13 22 17 9.6 21 NA NA NA
T3 (nmol/L) 0.64 0.45 1.20 0.49 0.20 0.78 NA NA NA
TSH (µmol/L) 7.7 3.9 19 6.7 3.9 15 NA NA NA
TBG (nmol/L) 920 590 1,300 880 620 1,300 NA NA NA
Abbreviations: GM, geometric mean; Max, maximum; Min, minimum; NA, not analyzed. Results
Recoveries of the internal recovery standards
([13C6]PCP and [13C12]HO-PCBs and
PCBs) were in the range of 75–104%. Mean
recovery of phenolic internal standards was
better than 87%. All concentrations were
recovery corrected.
With the Liliefors test for normal distrib-
ution, the chemical residue data were not
normally distributed. Thus, all data (includ-
ing retinol and thyroid hormone concentra-
tions) were log transformed before statistical
analysis. The regional concentration data are
summarized using geometric means along
with minimum and maximum values
(Tables 1–3)
Thirty compounds were characterized
as HO-PCBs in the umbilical cord plasma
samples. Concentrations of PCP and iden-
tified HO-PCB congeners are listed in
Table 1. Two congeners, 4-HO-CB107
and 4´-HO-CB108, coelute and were
quantitated as a single peak. The peak is
likely 4-HO-CB107, as demonstrated in
previous studies (16,30). ΣHO-PCBs repre-
sents a sum of all identiﬁed HO-PCBs and
all compounds characterized as HO-PCBs.
Unidentified HO-PCBs were quantitated
using relative response factors as described
previously (12). ΣHO-PCBs were analyzed
for regional differences by multiple analysis
of variance. Lower North Shore samples
had the highest mean concentration of
ΣHO-PCBs, which was signiﬁcantly higher
than concentrations in southern Québec
samples using the Sheffe test (p = 0.01).
The Nunavik samples were not signiﬁcantly
different from southern samples (p = 0.8)
or from Lower North Shore samples (p =
0.06). PCP concentrations were highest in
Nunavik samples but were not signiﬁcantly
different among regions.
We also found another compound
recently identified as a major chlorinated
phenolic compound in polar bear plasma, 4-
hydroxy-heptachlorostyrene (4-HO-HpCS)
(31), in the human umbilical cord plasma
samples (Table 1). This compound was
determined in all umbilical cord plasma
samples. No quantitative standard was avail-
able at the time of analysis, so we estimated
concentrations of 4-HO-HpCS using the
average heptachlorinated MeO-PCB
response factor. The geometric mean con-
centrations in Nunavik and Lower North
Shore samples were about six times higher
than in southern Québec samples.
Forty-nine PCB congeners with 5 or
more chlorines were above the detection
limit in most of the umbilical cord plasma
samples. Concentrations of all 49 PCBs and
ΣPCBs (sum of all congeners) are listed in
Table 2. The ratio of ΣHO-PCBs to ΣPCBs
is given in Table 1. ΣPCBs were highest in
Lower North Shore plasma samples and
Nunavik samples, but only Lower North
Shore samples were signiﬁcantly different (p
= 0.01) from southern Québec samples by
the Sheffe test. The mean ratio of ΣHO-
PCB metabolites to PCBs was highest in
southern Québec samples and lowest in
Nunavik samples, but the ratio was not sta-
tistically different among regions. 
ΣHO-PCBs and ΣPCBs concentrations
were highly correlated in umbilical cord
plasma (r = 0.69, p < 0.001), as shown in
Figure 2. Fractions of the main identified
HO-PCBs of ΣHO-PCBs are shown in
Figure 3. The PCBs from which the main
metabolites may be formed are listed above
each metabolite in Figure 3. 
Figure 4 shows the correlation between
one of the main HO-PCBs, 4-HO-CB146,
and its potential precursor PCBs. The
metabolite was significantly correlated (p <
0.001) with all possible precursor PCBs and
was signiﬁcantly correlated with many non-
related PCBs (not shown).
Mean retinol concentrations were lowest
in Nunavik samples and highest in southern
Québec samples, but differences between the
regions were not statistically significant
(Table 3). No significant correlations were
observed between concentrations of retinol
and any individual HO-PCB or PCB con-
geners, ΣHO-PCBs, sum of all chlorinated
phenolic compounds, or ΣPCBs. 
Plasma concentrations of T3, free T4,
TSH, and TBG were not signiﬁcantly differ-
ent between Lower North Shore and
Nunavik samples (Table 3). Concentrations
of main HO-PCBs and PCBs were not sig-
nificantly correlated with thyroid hormone
markers. In contrast, PCP concentrations
were negatively correlated with T3 (r =
–0.55, p = 0.01), TBG (r = –0.44, p = 0.05),
and free T4 levels (r = –0.51, p = 0.02).
Figure 5 shows the statistically significant
inverse correlation (r = –0.47, p = 0.01)
between free T4 concentrations and log-
transformed sum of all chlorinated phenolic
compounds (sum of PCP and ΣHO-PCBs).
The relationship was not improved using
log-free T4 and log-sum molar concentration
of phenolic compounds. The sum of all
chlorinated phenolic compounds was also
negatively associated with T3 concentrations
(r = –0.48, p = 0.03). Concentrations of
ΣPCBs and ΣHO-PCBs were both nega-
tively correlated with TSH concentrations (r
= –0.46, p = 0.04 and r = –0.45, p = 0.04,
respectively).
Discussion
Hydroxylated metabolites and other chlori-
nated phenolic compounds, to our knowl-
edge, have never been examined in umbilical
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Figure 2. Relationship between log-transformed
ΣHO-PCBs and ΣPCBs concentrations.
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Figure 3. Concentrations of major HO-PCBs in umbilical cord plasma expressed as the mean fraction of
ΣHO-PCBs. Error bars represent the SD. All potential precursor PCBs are given above each metabolite.
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Southern Québeccord plasma. We found that PCP was the
most abundant phenolic compound in all
three regions, representing an average of
78%, 66%, and 82% of the concentration of
the sum of all quantitated chlorinated phe-
nolic compounds in the Nunavik, Lower
North Shore, and southern Québec groups,
respectively. Mean PCP concentrations were
similar among groups, and individual values
ranged from 628 to 7,680 pg/g wet weight.
We previously reported PCP as the domi-
nant chlorinated phenolic compound in
blood samples from Nunavik and southern
Québec adults (12). Thus, PCP may super-
sede HO-PCBs as the chlorinated phenolic
compound of highest concern in humans. 
PCP and its salts have been used exten-
sively as wood preservatives, biocides, and
disinfectants (32). PCP use has been cur-
tailed since the late 1970s and has been
banned in some countries, such as Sweden
(1977) and Germany (1987) (32). The use
of PCP has been restricted in Canada since
1981. The main exposure to PCP for nonoc-
cupationally exposed individuals is through
the diet (33). Another significant source of
PCP may occur through the metabolism of
hexachlorobenzene (34). Plasma is the most
important compartment for PCP storage. In
dosed rats, 99% of PCP is bound to plasma
proteins (35). In human volunteers, the per-
centage of PCP bound to plasma proteins
was estimated to be 96% (36).
PCP can induce deleterious effects on
several organs or tissues. Increased lympho-
cyte responses were noted in patients with
high PCP blood levels (37). PCP can be
metabolized to reactive quinone metabolites
(38) with possible covalent binding to crude
liver homogenates and isolated liver proteins
in vitro (39). PCP has twice the affinity of
T4 to TTR (10) and has been shown to
decrease circulating T4 levels in rams
exposed from conception (40). PCP also
affects thyroid hormone metabolism by
competitively inhibiting iodothyronine sul-
fation in vitro (41). In the present study, the
sum of plasma concentrations of phenolic
compounds, the major part being PCP, were
negatively correlated to free T4 and T3
plasma levels. This suggests that PCP and
perhaps other chlorinated phenolic com-
pounds can alter thyroid hormone status in
newborns, which in turn could lead to
adverse neurodevelopmental effects in
infants.
Another chlorinated phenolic compound
recently identiﬁed by our laboratory in polar
bear plasma, 4-HO-HpCS (31), was also
found in all umbilical cord plasma samples
analyzed. This is the first time this com-
pound has been shown to be present in
human plasma. The likely precursor for this
compound is octachlorostyrene, an indus-
trial byproduct. The fact that lower concen-
trations of 4-HO-HpCS were found in the
southern Québec group than in the Nunavik
and Lower North Shore groups suggests that
the likely source of exposure is the consump-
tion of species from the marine food chain.
Sandau et al. (31) showed that this com-
pound had an afﬁnity similar to T4 for bind-
ing to TTR, which is slightly less than PCP
(10) and lower than most HO-PCBs that
have been determined (42).
Concentrations of ΣHO-PCBs in umbil-
ical plasma were highest in the Lower North
Shore samples. More than 30 compounds
were identified as HO-PCBs, of which 11
were positively identified with authentic
standards. Three more HO-PCBs found in
humans (16) were tentatively identiﬁed but
could not be conﬁrmed because no authentic
standards were available. The main metabo-
lite in 27 of the 30 samples was 4-HO-
CB187. This compound was also the
dominant metabolite in fish eaters from
Sweden, Black-footed and Laysan albatross,
and polar bear (13,43,44). Two possible par-
ent PCBs can form 4-HO-CB187 through
two different hydroxylation mechanisms.
The ﬁrst involves the direct insertion (45) of
a hydroxyl group onto the para position of
CB187. Direct insertion has been demon-
strated to occur in in vitro metabolism stud-
ies of halobenzenes (46) and CB52 (47).
CB187 is an abundant congener found in
biota and accounted for a mean of 3.4% of
the ΣPCBs in all the umbilical cord plasma
samples. It is found as a small percentage
(0.54%) in the Aroclor 1254 mixture, but is
more abundant in Aroclor 1260 (5.4%)
(48). The second mechanism of oxidation is
the formation of a 3,4 (meta-para)-epoxide
in CB183 followed by a 3,4 shift of chlorine
to the meta position similar to the National
Institutes of Health (NIH) shift of 2H first
described by Guroff et al. (49). Epoxide for-
mation in the metabolism of PCBs has been
demonstrated in in vitro studies (50) as well
as in vivo studies (17) using CB77 as sub-
strate. CB183 composed a mean of 0.8% of
the ΣPCBs in the umbilical cord plasma and
constitutes approximately 0.2% and 2.4% of
Aroclor 1254 and 1260 mixtures, respectively
(48). Interestingly, the major PCB metabolite
in umbilical cord plasma, 4-HO-CB187, is
formed from PCBs that make up a small per-
centage of the ΣPCBs in the samples.
The second most abundant metabolite in
umbilical cord plasma was 4-HO-CB146.
This metabolite can be formed by direct
insertion onto CB146 or by NIH shift of
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Figure 4. Relationship between log-transformed concentrations of precursor
PCBs (CB146, 153, and 138) and the second most abundant metabolite in umbil-
ical cord plasma, 4-HO-CB146. CB138 coelutes with CB163 and they were
quantitated as a single peak.
Figure 5. Relationship between log-transformed concentrations of free T4 and
sum of all chlorinated phenolic compounds (sum PCP and ΣHO-PCBs).
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Lower North Shorechlorine in the metabolism of CB138 or
CB153. These three parent PCBs compose a
large percentage of the ΣPCBs (between 11
and 47%) quantitated in all the samples.
CB153 (mean 15% of ΣPCBs) and CB138
(mean 8.3% of ΣPCBs) are the two most
abundant PCBs determined in the plasma
samples and are major components in
Aroclor mixtures (48). All three potential
parent PCBs were significantly (p < 0.001)
correlated with 4-HO-CB146 (Figure 4). 
The third most abundant metabolite was
4-HO-CB107, which can be formed from
CB107 (direct insertion), CB105 (NIH-Cl
shift), or CB118 (NIH-Cl shift). Both
CB105 and CB118 are major congeners in
Aroclor 1254, composing 5.2% and 10.5%
of the total (48). CB107 is a minor congener
in Aroclor 1254 (0.6%), and it is rarely
found in environmental samples, including
these umbilical cord plasma samples.
Concentrations of the potential parent PCBs
CB105 (mean 1.3% of ΣPCBs) and CB118
(mean 4.8% of ΣPCBs) were significantly
correlated (r = 0.69, r = 0.81, respectively; p
< 0.001) with 4-HO-CB107 concentrations.
In contrast to our study results, 4-HO-
CB107 was previously found to be the main
metabolite in adult Inuit whole blood,
Latvian fish consumers, Baltic seals, white-
tailed eagles, and rats dosed with Aroclor
1254 (12,13,16,30). 
The relationship between metabolites
and their potential precursor PCBs could
not be resolved further using multiple-step
regression analysis (forward or backward).
Concentrations of major metabolites were
highly correlated with all PCBs, even unre-
lated congeners. Therefore, it is not possible
from the present data to determine which
congeners are the precursors of the metabo-
lites—that is, the relative importance of
NIH chlorine shift to direct insertion.
Hydroxylated PCB patterns vary among
individuals (12,13). This variation can be
caused by selective retention or selective for-
mation of metabolites or by differences in
PCB exposure. The retention of specific
HO-PCBs is probably similar for all
humans. The main structural requirement
for retention is the capability to bind to
TTR (9). This requirement is thought to
involve a hydroxyl group with adjacent chlo-
rines (42). The hydroxyl group is often in the
para position of the biphenyl ring, but not
exclusively, because meta-substituted metabo-
lites are also found in plasma. Humans have
varying concentrations of TTR in plasma,
and some genetic abnormalities are known
(51). Generally, concentrations are in excess
molar concentration to HO-PCBs (12).
Thus, the main determinant of the pattern of
HO-PCBs in blood is likely the formation of
metabolites from the parent PCB congeners.
It was interesting to note that the geo-
metric mean ratio of ΣHO-PCBs to ΣPCBs
concentrations was similar (~ 0.2) among
regions. The ratio was twice that found in a
previous study involving whole blood of
Canadian Inuit (0.11) (12). Because the rela-
tionship of the log-transformed concentra-
tions in umbilical cord plasma had a slope of
between 0.5 and 0.6 (Figures 2 and 4), the
ratio of metabolites to PCBs decreased with
increasing PCB concentrations. The range
was from approximately 0.4 at low PCB
concentrations (500 pg/g; Figure 2) to
approximately 0.1 at high PCB concentra-
tions (5,000 pg/g; Figure 2), similar to that
found in adult whole blood. There was no
apparent effect of PCB concentration on the
ratio of metabolites to PCBs in adult whole
blood (15). The generally higher ratio in
umbilical cord plasma samples may reflect
the difference in composition of fetal and
adult blood. For example, umbilical cord
plasma has approximately half the lipid con-
tent and less transthyretin than adult plasma
(52). It has been shown previously that PCBs
are most concentrated in plasma lipoproteins
(53). Another possible explanation for the
differences in the metabolite/PCB ratio in
adult and fetal blood could involve enhanced
placental transfer of HO-PCBs from the
mother. The transfer of PCB metabolites
from dosed mice to the fetus was tested by
Sinjari et al. (20). They showed that 4´-HO-
CB79 concentrations in fetal plasma were
twice that of the maternal plasma, 24 hr after
exposure, indicating enhanced transport of
the metabolite, which likely occurs through
binding to TTR. 
When the individual chemical residue
data were compared to thyroid hormone
markers, only PCP concentration was signiﬁ-
cantly related to T3, free T4, and TBG con-
centrations. PCP has twice the afﬁnity of T4
to TTR (10) and can affect thyroid hormone
concentrations in rats (54). PCP has also been
shown to affect thyroid hormone metabolism
by competitively inhibiting iodothyronine
sulfation in vitro (41). When concentrations
of all phenolic compounds were summed and
correlated with the thyroid hormone markers,
only T3 and free T4 concentrations were neg-
atively associated, and the signiﬁcance of the
regression increased. The negative association
between free T4 and the sum of all phenolic
compounds is in agreement with the theory
that HO-PCBs and other chlorinated pheno-
lic compounds disrupt thyroid hormone
transport through the common mechanism of
binding to TTR. In addition to binding to
TTR, halogenated phenolic compounds may
disrupt thyroid hormone metabolism (14,41).
Morse et al. (55) found that both mater-
nal and neonatal rats showed decreased total
and free T4 levels with exposure to CB169
and/or CB77 in a dose-dependent manner.
They concluded that fetal T4 levels were
affected by both reduced transplacental
delivery of T4 and increased T4 metabolism
by the induced glucuronyltransferase
enzymes. Darnerud et al. (56) also demon-
strated fetal reduction in total T4 and free T4
when pregnant mice were dosed with CB77.
Furthermore, Dutch infants showed
decreased free and total T4 levels with
increased PCB/dioxinlike compound expo-
sure (23). Thus, many studies indicate that
T4 concentrations can be decreased by expo-
sure to PCBs, and this study supports the
theory that HO-PCBs, and perhaps other
halogenated phenolic compounds, may be
partly responsible for this decrease.
TTR has been shown to be important in
T4 transport in cerebral spinal fluid (7). If
chlorinated phenolic compounds can signiﬁ-
cantly alter plasma levels of TTR-bound T4,
this may lead to brain thyroid hormone deﬁ-
ciencies in utero, possibly affecting brain devel-
opment (57). TTR is also important in
thyroid hormone transport across the placental
barrier (58). Maternal sources of thyroid hor-
mones are thought to influence fetal brain
development (59). The binding of metabolites
to TTR may also improve transport of halo-
genated phenolic compounds across the pla-
centa, as has been shown in mice (19). Thus,
phenolic compounds may be able to disrupt
maternal sources of thyroid hormones, pene-
trate into fetal circulation, and disrupt local
thyroid hormone supply in the developing
fetus. The potential of PCP and HO-PCBs to
disrupt thyroid hormone homeostasis in the
developing fetus warrants further investigation
to conﬁrm the effects observed in the present
study. A study is currently underway that will
examine the relationship between halogenated
phenolic compounds, thyroid hormones, and
retinol concentrations in newborns from a
larger cohort.
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